![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) |
|
Phase II Study of Observation in Patients With Favorable Low-Grade Glioma and a Phase III Study of Radiotherapy With or Without Procarbazine, Lomustine, and Vincristine in Patients With Unfavorable Low-Grade Glioma
Alternate Title Basic Trial Information Objectives Entry Criteria Expected Enrollment Outline Published Results Trial Contact Information Registry Information
Alternate Title
Observation or Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Low-Grade Glioma
Basic Trial Information
![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) |
Phase
![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) |
Type
![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) |
Status
![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) |
Age
![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) |
Sponsor
![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) |
Protocol IDs
![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif)
Phase III, Phase II
![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif)
Treatment
![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif)
Closed
![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif)
18 and over
![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif)
NCI
![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) |
![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif)
RTOG-9802 E-R9802, NCCTG-R9802, SWOG-R9802, RTOG-DEV-1012, NCT00003375, RTOG-98-02
![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif)
|
![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) |
|
Objectives - Identify the overall survival of low-risk adult patients with supratentorial low-grade glioma who are observed postoperatively.
- Compare the overall survival of high-risk adult patients with supratentorial low-grade glioma who receive postoperative external beam radiotherapy with or without procarbazine, lomustine, and vincristine (PCV) chemotherapy.
- Compare the toxic effects of postoperative radiotherapy with or without PCV chemotherapy in patients with unfavorable low-grade glioma.
Entry Criteria Disease Characteristics:
- Histologically confirmed unifocal or multifocal supratentorial WHO grade
II
astrocytoma (diffuse fibrillary, protoplasmic, or gemistocytic),
oligodendroglioma, or oligoastrocytoma
- Patients with neurofibromatosis are eligible
- No other low-grade histologies, including:
- Pilocytic astrocytoma
- Subependymal giant cell astrocytoma of tuberous
sclerosis
- Subependymoma
- Pleomorphic xanthoastrocytoma
- Presence of a neuronal element such as ganglioglioma
- Dysneuroembryoplastic epithelial tumor
- No presence of any high-grade glioma, including:
- Anaplastic astrocytoma
- Glioblastoma multiforme
- Anaplastic oligodendroglioma
- Anaplastic oligoastrocytoma
- No tumors in nonsupratentorial or other locations including optic chiasm,
optic nerve(s), pons, medulla, cerebellum, or spinal cord
- No evidence of spread to spinal meninges or noncontiguous cranial
meninges
(i.e., leptomeningeal gliomatosis)
- No gliomatosis cerebri
Prior/Concurrent Therapy:
Biologic therapy: Chemotherapy: Endocrine therapy: Radiotherapy: - No prior radiotherapy to the head or neck (unless
brain is clearly excluded, such as radiotherapy for localized vocal
cord cancer)
Surgery: Patient Characteristics:
Age: Performance status: Hematopoietic: - For high-risk patients:
- Granulocyte count at least 1,500/mm3
- Platelet count normal
Hepatic: - Bilirubin no greater than 2 times normal
- SGOT or SGPT no greater than 4 times normal
- Alkaline phosphatase no greater than 2 times normal
Renal: - Creatinine no greater than 2 times normal
Pulmonary: - No chronic lung disease (unless DLCO at least 60%)
Neurological: - Neurologic function score no greater than 3
Other: - Not pregnant or nursing
- Fertile patients must use effective contraception
- No other malignancy within the past 5 years except carcinoma in situ of
the cervix or nonmelanoma skin cancer
- No active infection
Expected Enrollment 252Approximately 252 patients will be accrued within 5.25 years. Outline This is a randomized study. Patients are stratified according to tumor
subtype (astrocytoma [mixed-astro dominant or equal astro/oligo mix] vs oligodendroglioma
[mixed-oligo dominant]), age (younger than 40 vs at least 40), Karnofsky
performance status (60-80% vs 90-100%), and contrast enhancement on
preoperative scan (present vs absent). Patients with low-risk disease (younger than 40 years old
whose tumors have been surgically removed) are assigned to arm I. Patients with high-risk disease (at least 40 years old or who have had incomplete tumor removal) are randomized to arm II or III. - Arm I (low-risk patients): Patients are observed. Patients
may receive treatment if tumor recurs.
- Arm II (high-risk patients): Patients receive daily
external beam radiotherapy 5 days a week for 6 weeks.
- Arm III (high-risk patients): Patients receive radiotherapy as in arm II followed by chemotherapy 1
month later. Chemotherapy consists of oral lomustine on day 1, vincristine IV on days 8 and 29, and oral procarbazine on days 8-21.
Each course of chemotherapy lasts 8 weeks. Patients may receive up to 6
courses of chemotherapy.
Patients are followed every 4 months for 1 year, every 6 months for
2 years, and then annually thereafter. Published ResultsShaw EG, Wang S, Coons S, et al.: Final report of Radiation Therapy Oncology Group (RTOG) protocol 9802: radiation therapy (RT) versus RT + procarbazine, CCNU, and vincristine (PCV) chemotherapy for adult low-grade glioma (LGG). [Abstract] J Clin Oncol 26 (Suppl 15): A-2006, 2008. Shaw EG, Berkey B, Coons SW, et al.: Initial report of Radiation Therapy Oncology Group (RTOG) 9802: prospective studies in adult low-grade glioma (LGG). [Abstract] J Clin Oncol 24 (Suppl 18): A-1500, 2006.
Trial Contact Information
Trial Lead Organizations Radiation Therapy Oncology Group ![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) | ![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) | ![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) | Edward Shaw, MD, Protocol chair | ![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) | | ![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) |
Southwest Oncology Group ![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) | ![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) | ![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) | Geoffrey Barger, MD, Protocol chair | ![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) | | ![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) |
North Central Cancer Treatment Group ![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) | ![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) | ![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) | Jan Buckner, MD, Protocol chair | ![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) | | ![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) |
Eastern Cooperative Oncology Group ![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) | ![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) | ![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) | Minesh Mehta, MD, Protocol chair | ![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) | | ![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) |
Registry Information | ![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) | Official Title | | A Phase II Study of Observation in Favorable Low-Grade Glioma and a Phase II Study of Radiation With or Without PCV Chemotherapy in Unfavorable Low-Grade Glioma | ![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) | Trial Start Date | | 1998-10-31 | ![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) | Registered in ClinicalTrials.gov | | NCT00003375 | ![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) | Date Submitted to PDQ | | 1998-06-22 | ![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) | Information Last Verified | | 2002-11-22 | ![](https://webarchive.library.unt.edu/eot2008/20081017110057im_/http://www.cancer.gov/images/spacer.gif) | NCI Grant/Contract Number | | CA21661 |
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. Back to Top |
![](images/spacer.gif) |